(NYSE: EVMN) Evommune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 75.28%.
Evommune's earnings in 2026 is -$68,870,000.On average, 10 Wall Street analysts forecast EVMN's earnings for 2026 to be -$101,661,855, with the lowest EVMN earnings forecast at -$118,248,315, and the highest EVMN earnings forecast at -$81,311,475.
In 2027, EVMN is forecast to generate -$117,319,041 in earnings, with the lowest earnings forecast at -$129,190,697 and the highest earnings forecast at -$106,650,399.